Chinese CRO forms international links
This article was originally published in Scrip
Executive Summary
Tigermed Consulting, one of China's largest pharmaceutical contract research organisations, has formed an alliance with similar firms in Russia and South Korea. It has teamed up with Saint Petersburg-based OCT and LSK in Seoul to provide services to multinational and Chinese firms looking to expand into Russia, Ukraine and eastern Europe and other Asian markets. The three CROs offer a variety of clinical development, regulatory and consulting services, and Tigermed said the network would bolster its internationalisation efforts. The Chinese venture capital group Qiming Venture Partners is among the private firm's investors.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.